BMS Fast Tracks CAR-T Manufacturing With Cellares Deal
In a partnership worth $380m, BMS has reserved clinical and commercial capacity with Cellares, a company whose $255m series C round it participated in last year.
In a partnership worth $380m, BMS has reserved clinical and commercial capacity with Cellares, a company whose $255m series C round it participated in last year.